Source: https://patents.google.com/patent/US6379651?oq=flatulence
Timestamp: 2018-04-26 00:18:45
Document Index: 248009937

Matched Legal Cases: ['art 1998', 'in Fine', 'art 2', 'art 2', 'art 1', 'in Fine']

US6379651B1 - Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases - Google Patents
Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases Download PDF
US6379651B1
US6379651B1 US09364613 US36461399A US6379651B1 US 6379651 B1 US6379651 B1 US 6379651B1 US 09364613 US09364613 US 09364613 US 36461399 A US36461399 A US 36461399A US 6379651 B1 US6379651 B1 US 6379651B1
US09364613
Bismuth compounds embodied in these inventions also have been found to stimulate cellular production of growth factors, and therefore have applications in wound healing, specifically in ocular and dermal wound healing. Therefore, the present invention also contemplates use of novel bismuth complexes with sulfated polyhydroxy hydrophilic film-forming polymers to accelerate wound healing in ulcerative diseases of the eye, skin, and other mucosal tissues. For these embodiments, the invention involves synthesis of unique complexes of bismuth with partially sulfated hydrophilic film-forming polymers such as hydroxyprobal cellulose, hydroxyethyl cellulose, hydroxypropyl-methyl cellulose, carboxymethyl cellulose, and polyvinyl alcohol. These compounds are formulated in unique film-forming solutions, aerosols, and gels for treatment of corneal ulcers, skin ulcers, gastric ulcers, and other wounds of the skin and mucous membranes. The general structures of this class of complexes are represented below:
Total: 2502.5 mg 2492.5 mg
formula-1 0 4.4
1 3.3 900.7 1270.3 148.7
(±1.4) (±239.1) (±334.7) (±42.0)
5 5.4 257.7 363.3 45.0
(±1.5) (±112.3) (±158.9) (±19.9)
10 4.9 28.0 40.0 5.0
(±1.3) (±5.0) (±6.6) (±1.0)
15 5.2 15.8 25.7 3.1
(±2.1) (±17.8) (±23.0) (±2.7)
formula-2 0 7.2
1 4.8 888.3 1257.0 156.3
(±1.9) (±329.5) (±464.5) (±58.0)
5 8.5 326.0 572.7 63.7
(±1.7) (±113.3) (±159.7) (±19.9)
10 7.5 30.0 42.3 5.0
(±3.4) (±9.5) (±13.6) (±1.7)
15 7.7 10.7 14.7 1.8
(±3.8) (±6.7) (±9.2) (±1.2)
(0 = dislike extremely, (±1.2) (±2.0) (±1.5) (±0.6)
TIME/CONDITION TIME (min) VOLUME (mL) (ppm) (μg/mL) CBS (μg/mL) X MIC
1 4.9 (±4.5) 1937.3 (±753.5)  1937.3 (±753.5)  2729.0 (±1060.2) 341.0 (±132.7)
40° C. 1 2.9 (±1.8) 1922.3 (±511.8)  1922.3 (±511.8)  2710.0 (±791.9)  338.6 (±90.3)
10 5.3 (±1.4) 25.7 (±11.4) 30.0 (±9.5)  362.0 (±160.5) 45.4 (±20.1)
15 4.9 (±0.4) 7.9 (±4.9) 10.7 (±6.7)  10.8 (±6.8)  1.4 (±0.9)
3 MONTHS 0 5.1 (±1.3) NA NA NA NA
ROOM TEMP. 1 4.1 (±1.5) 1240.0 (±458.7)  1240.0 (±458.7)  1748.0 (±646.6)  218.0 (±80.6)
15 5.6 (±1.6) 4.5 (±2.2) 4.5 (±2.2) 6.0 (±2.2) 0.7 (±0.3)
SENSORY CHEWING TIME
CHARACTERISTIC 1 MIN 5 MIN 10 MIN 15 MIN
UNPLEASANT 0.0 (±0.0) 0.0 (±0.0) 0.0 (±2.1) 0.0 (±0.0)
UNPLEASANT 0.3 (±0.6) 0.3 (±0.6) 0.0 (±0.0) 0.0 (±0.0)
UNPLEASANT 0.0 (±0.0) 0.0 (±0.0) 0.0 (±0.0) 0.0 (±0.0)
Test Lot Stability Lot Lot
50CG- Zero 3 mo./ 3 mo./ 50CG-
0001 Time RT 40° C. 0003
K (pseudo first −0.339 −0.432 −0.361 −0.448 −0.426
Mean t0.5 = 1.748 (± 0.218)
Zero 3 mo./ 3 mo./ # CBS-
Time RT 40° C. 50CG-0003
Mg CBS/2.5 g gum 45.6 44.5 46.1 46.2
Before chewing (%) (100) (100) (100) (100)
Mg CBS/2.5 g gum 3.5 4.0 4.5 3.8
After 15 min (7.6) (9.0) (9.8) (100)
Phosphoric Acid to adjust pH to QS
Healthy human volunteers are given either a placebo chewing gum or a chewing gum containing antibiotic/antibacterial. Saliva samples are collected at 0, 5, 10, and 15 minutes of chewing and analyzed for antibiotic or antibacterial concentration. The results are expressed in mcg/mL and also expressed as a multiple of minimum inhibitory concentration (MIC) of the agent for H. pylori. The salivary concentrations of the agent remain above the MIC level at 1, 5, 10 and 15 minutes, respectively. The constant bathing of the oral cavity from saliva containing sufficient concentration of the agent (several times the MIC) for up to 15 minutes can be expected to eradicate or reduce the viable cells of H. pylori.
Sensory characteristics of the chewing gum are evaluated by the subjects during the 15 minutes of chewing. Again, half the subjects chew the placebo gum, and the other half of the subjects chew the gum containing antibiotic/antibacterial. A nine point rating scale is used to evaluate each category.
Ascorbyl Bismuth
1. In a method of treating Helicobacter Pylori infection by administering and ingesting peroral tablets of an antibiotic/antibacterial compound with a Bismuth compound, the improvement comprising concornitantly administering and chewing within an oral cavity an antibiotic/antibacterial compound with a Bismuth compound in a topical chewing gum dosage form which releases the antibiotic/antibacterial into the oral cavity in a concentration sufficient to reduce or eliminate the Helicobacter Pylori in the oral cavity, said Bismuth compound being selected from the group consisting of colloidal bismuth subcitrate, bismuth subcitrate, bismuth citrate, bismuth salicylate, bismuth subsalicylate, bismuth subnitrate, bismuth subcarbonate, bismuth tartrate, bismuth subgallate, tripotassium dicitrato bismuthate, bismuth aluminate, bismuth polysulfate complexes, bismuth polyhydroxy complexes, alpha-D-glucopyranoside bismuth complex, beta-D-fructofuranosyl-oktakis (hydrogen sulfate) bismuth complex, and L-dihydro ascorbyl-tetrakis (hydrogen sulfate) bismuth complex, said antibiotic/antibacterial compound being selected from the group consisting of Nicin peptides, Nicin-related peptides, Tetracycline, Amoxycillin, Ampicillin, Doxycycline, Erythromycin, Clarithromycin, Metronidazole, Tinidazole, Ciproflaxacin, Oflaxacin, Norflaxacin, Furazolidine, and Nitrofurantoin.
US09364613 1995-02-07 1999-07-29 Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases Expired - Lifetime US6379651B1 (en)
US82756697 true 1997-03-28 1997-03-28
US5064398 true 1998-03-30 1998-03-30
US09364613 US6379651B1 (en) 1995-02-07 1999-07-29 Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
US5064398 Continuation-In-Part 1998-03-30 1998-03-30
US6379651B1 true US6379651B1 (en) 2002-04-30
ID=27489347
US09364613 Expired - Lifetime US6379651B1 (en) 1995-02-07 1999-07-29 Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
US (1) US6379651B1 (en)
WO2008004224A2 (en) * 2006-07-03 2008-01-10 Arie Levine Synergistic compositions for crohn's disease and inflammatory gastrointestinal disorders
US20160324765A1 (en) * 2015-04-14 2016-11-10 Kenneth Davin Fine Dental hygiene systems
"Campylobacter pylori Becomes Helicobacter pylori" The Lancet, Oct. 28, 1989 pp. 1019-1020.
Abraham et al. "Helicobacter pylori in its lair: a role in ulcer recurrence?" Indian Journal of Gastroenterology (1990) vol. 9, No. 4, pp. 265-266.
Andersen et al. "Campylobacter pylori in Peptic Ulcer Disease. II. Endoscopic Findings and Cultivation of C. pylori." Scand. J. Gastroenterol. (1988), pp. 760-764.
Beil et al. Studies on the Mechanism of Action of Colloidal Bismuth Subcitrate II. Interaction with Pepsin and I Interaction with Sulfhydryls, Pharmacology, (1993) vol. 47, pp. 135-140, 141-144.
Benet "Safety and Pharmacokinetics: Colloidal Bismuth Subcitrate", Scand. J. Gastroenterol (1991) vol. 26, Suppl., No. 185, pp. 29-35.
Bettarello "Anti-ulcer therapy. Past to present" Digestive Diseases and Sciences (Nov. 1985) vol. 30, No. 11, suppl. pp. 36S-42S.
Blaser et al. "Campylobacter Enteritis" New England Journal of Medicine (1981) vol. 305, pp. 1444-1452.
Bornkessel "Helicobacter pylori bie Ulkuserkrankungen" Aeimitteltherapie (13.Jahrgang/Heft1/1995) pp. 17-19 [in German].
Borody et al. "High Efficacy, Low Dose Triple Therapy (TT) for Helicobacter pylori (HP)" Gastroenterology (1992) vol. 102, No. 4, part 2, p. A44 [abstract only].
Börsch et al. "Helicobacter pylori" Pharmacology of peptic ulcer disease, Chapter 5, (1991) pp. 107-147.
Bosy et al. "Relationship of Oral Malodor to Periodontitis: Evidence of independence in discrete subpopulations" J. Periodontol (1994) vol. 65, No. 1 pp. 37-46.
Bouvet "Bismuth salts used in gastro-enterology. Data of animal investigations" Ann. Pharm. Fr (1980), vol. 38, No. 5, pp. 447-454 [in French with English summary].
Boyd et al. "Recurrent ulcer disease" Gastroenterology Clinics of America. Helicobacter pylori Infection (Mar. 1993) Chapter 2, vol. 22, No. 1, pp. 14-42.
Breuer et al. "Epidemiologie und Pathogenese der Helicobacter pylori-infektion" GASTRO-LIGA Report (Mar./Apr. 1994) pp. 1-5 [in German].
Coghill et al. "The ultrastructural localization of De-Nol (colloidal tripotassium dicitrato-bismuthate-TDB) in the upper gastrointestinal tract of man and rodents following oral and instrumental administration" Chemical Abstracts Service (1983) vol. 98, p. 15, No. 172475y [abstract only].
Colson "The treatment of chronic colitis and colopathies by a new association of bismuth, mucilage, oxyquinoline and meprobamate" Revue des corps de santé des Armées (Apr. 1966) vol. 7, No. 2, p. 319-334 [English translation of the French article].
Dixon "[Part] IV. Helicobacter pylori and peptic ulceration: histopathological aspects" Journal of Gastroenterology and Hepatology (1991) vol. 6, pp. 125-130.
Drumm et al. "Association of Campylobacter pyroli on the Gastric Mucosa With Antral Gastritis in Children" The New England Journal of Medicine (Jun. 18, 1987), vol. 316, No. 25, pp. 1557-1561; 1598-1599.
Eberhardt et al. "Effect of oral bismuthsubsalicylate on Campylobacter pyloridis and on duodenal ulcer" Gastroenterology (May 1987) vol. 92, No. 5, part 2, p. 1379 [abstract only].
Forman et al. "An international association between Helicobacter pylori infection and gastric cancer" The Lancet (May 29, 1993) vol. 341, No. 8857, pp. 1359-1362.
Freedberg et al. "The Presence of Spirochetes in Human Gastric Mucosa" American Journal of Digestive Diseases (1940) vol. 7, No. 10, pp. 443-445.
Gisselbrecht et al. "Treatment of constipation and colitis by the association of bismuth subnitrate and Karaya gum" Lyon Med., (May 3, 1970) vol. 223, No. 18, pp. 951-958 [French article and English translation].
Goodman, The Pharmacological Basis of Therapeutics. Fifth edition. (1975) pp. 930, 997-998.
Goodwin "Taxonomy of Helicobacter pylori and related bacteria" Helicobacter pylori, gastritis and peptic ulcer (1990) pp. 3-8.
Goodwin et al. "Clearance of Campylobacter pylori and reduced duodenal ulcer relapse with bismuth and tinidazole compared to cimetidine", Abstract No. 60, IVth International Workshop on Campylobacter Infections, Goteberg, Sweden, Jun. 1987, pp. 368-369.
Gorback "Bismuth therapy in gastrointestinal diseases" Gastroenterology (Sep. 1990) vol. 99, No. 3, pp. 863-875.
Graham "Helicobacter pylori: human pathogen or simply an opportunist?" The Lancet (Apr. 29, 1995) vol. 345, pp. 1095-1097.
Hamilton et al. "Effects of tripotassium dicitrato bismuthate (TDB) tablets or cimetidine in the treatment of duodenal ulcer" Gut (Dec. 1983) vol. 24, No. 12, pp. 1148-1151.
Hëraud et al. "Therapeutical trial of an association of an insoluble bismuth salt and a Karaya gum in gastro-intestinal pathology" Lille Medical, 3rd Series, (1969) vol. XIV, No. 6, supplement, pp. 677-679 [French article with English translation].
Hosking et al. "Duodenal Ulcer Healing by Eradication of Helicobacter pylori without anti-acid treatment: radomised controlled trial" The Lancet (1994) vol. 343, pp. 508-510.
Jones et al. "Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs" Gut (1987), vol. 28, pp. 1120-1127.
Lambert et al. "Effect of Colloidal Bismuth (De-Nol) on Healing and Relapse of Duodenal Ulcers—Role of Campylobacter pyloridis", Abstract No. 91, IVth International Workshop of Campylobacter Infections, Goteberg, Sweden, Jun., 1987, p. 383.
Lambert, J.R. "Clinical Indications and Efficacy of Colloidal Bismuth Subcitrate" Scand. J. Gastroenterol (1991) vol. 26, supp. 185, pp. 13-20.
Lambert, J.R. et al. "Helicobacter pylori" Mechanisms of Injury, Protection and Repair of the Upper Gastrointestinal Tract (1991), p. 19-28.
Langenberg et al. "Campylobacter-like Organisms in the Stomach of Patients and Healthy Individuals" The Lancet (Jun. 16, 1984) vol. 1 pp. 1348-1349; 1336-1337.
Lee, F.I. et al. "Comparison of Tri-potassium Di-citrato Bismuthate Tablets with Ranitidine in Healing and Relapse of Duodenal Ulcers" The Lancet (Jun. 8, 1985) vol. 1, pp. 1299-1302.
Lee, S.P. "The Mode of Action of Colloidal Bismuth Subcitrate" Scand. J. Gastroenterol (1991) vol. 26, supp. 185, pp. 1-6.
Lee, S.P. et al. "Increased healing of gastric and duodenal ulcers in a controlled trial using tripotassium dicitrato-bismuthate" Med J. Aust (May 28, 1997) vol. 1, No. 22, pp. 808-809; 812.
Lees et al. "A freeze-injured skin graft model for the quantitative study of basic fibroblast growth factor and other promoters of angiogenesis in wound healing" British Journal of Plastic Surgery (1994) vol. 47, pp. 349-359.
Logan et al. "One week eradication regimen for Helicobacter pylori" The Lancet (Nov. 16, 1991) vol. 338, pp. 1249-1252.
Marcheggiano, et al. "Campylobacter-Like Organisms (CLOs) Gastritis and Peptic Ulcer", Abstracts of Papers, (May 1986) p. 1533, [abstract only].
Marshall "Treatments strategies for Helicobacter pylori Infection" Gastroenterology Clinics of America. Helicobacter pylori infection. vol. 22, No. 1, pp. 186-195.
Marshall et al. "Histological improvement of Active Chronic Gastritis in Patients Treated with De-Nol" Australia J. of Medicine (Dec. 1984) vol. 14, p. 907; New England J. of Medicine (Dec. 10, 1981), p. 1452.
Marshall et al. "Unidentified Curved Bacilli in the Stomach of Patients with Gastritis and Peptic Ulceration" The Lancet (Jun. 16, 1984) vol. 1, pp. 1311-1315.
Matuszewska et al. "Acidic Fibroblast Growth Factor: Evaluation of Topical Formulations in a Diabetic Mouse Wound Healing Model" Pharmaceutical Research (1994), vol. 11, No. 1, pp. 65-71.
McLean et al. "Microbes, Peptic Ulcer, and Relapse Rates With Different Drugs", The Lancet, Sep. 1, 1984, pp. 525-526.
McNulty et al. "Successful therapy of Campylobacter pyloridis gastritis" Abstracts of Papers (May 1986), p. 1547 [abstract only].
Morris, A.; Brown, P.; Ali, M. R.; Lane, M.; Palmer, R. "Treatment of Campylobacter pylori gastritis: a pilot study using pirenzepine dihydrochloride (Gastrozepin) and three formulations of collolidal bismuth subcitrate (De-Nol)", The New Zealand Medical Journal, Oct. 26, 1988, vol. 101, No. 856, part 1, pp. 651-654.
Navarranne "Treatment of spasmodic and psychosomatic colopathies by a cicatrisant, antiseptic and anxiolytic medication combination" Therapie (1967) vol. XXII, pp. 419-426, English Translation.
Patty, et al. "A controlled clinical trial with De-Nol (tripotassium dicitrato bismuthate) in patients with gastric ulcer" Int J. Tissue Reac (1983) V(4), pp. 397-401.
Piper, "Bacteria, gastritis, acid hyposecretion and peptic ulcer" The Medical Journal of Australia, vol. 142, Apr. 15, 1985, p. 431.
Rauws, et al "Cure of duodenal ulcer associated with eradication of Helicobacter pylori" The Lancet, vol. 335, pp. 1233-1235, May 26, 1990.
Recavarren-Arce et al. "Helicobacter pylori and progressive gastric pathology that predisposes to gastric cancer" Scand. J. of Gastroenterol (1991) vol. 26, supp. 181, pp. 52-57.
Reed et al. "Effect of ascorbic acid on the intragastric environment in patients at increased risk of developing gastric cancer" Relevance to Human Cancer of N-Nitroso Compounds, Tobacco Smoke and Mycotoxins (ed. By O'Neill et al.) (1991), pp. 139-142.
Rosenberg et al. "Day-Long Reduction of Oral Malodor by a Two-Phase Oil: Water Mouthrinse as compared to chlorhexidine and placebo rinses" J. Periodontol (1992) vol. 63, No. 1, pp. 39-43.
Schorah et al. "Gastric juice ascorbic acid: effects of disease and implications for gastric carcinogenesis" Am. J. Clin. Nutr. (1991) vol. 53, pp. 287S-293S.
Shreeve et al. "Comparison of cimetidine and tripotassium dicitrato bismuthate in healing and relapse of duodenal ulcers" Digestion (1983) vol. 28, pp. 96-101.
Steinhoff et al. "Bismuth Subsalicylate Therapy of Viral Gastroenteritis" Gastroenterology (Jun. 1980) vol. 78, No. 6 pp. 1495-1499.
Stolte "Helicobacter pylori-syndrom: von der gastritis bis hin zum malignom" (May 1992) pp. 3-10 [in German].
Sutton. "Gastric ulcer healing with tripotassium dicitrato bismuthate and subsequent relapse" Gut vol. 23 (1982), pp. 621-624.
Tytgat et al. "Campylobacter pylori Diagnosis and Treatment" Journal Clinical Gastroenterol, vol. 11, Suppl. 1, 1989, pp. S49-S53.
Tytgat et al. "DE-NOL® in the treatment of peptic ulcer. Proceedings of the DE-NOL® symposium" Scand J of Gastroenterology (Jun. 15, 1982), pp. iv, 1-61.
Tytgat et al. "Helicobacter pylori: Causal agent in peptic ulcer disease?" Working Party Reports, (1990) pp. 36-45.
Warren, J. with reply from B. Marshall "Unidentified Curved Bacilli on Gastric Epithelium in Active Chronic Gastritis" The Lancet (Jun. 4, 1983) vol. 1 p. 1273-1275.
Wieriks et al. Pharmacological Properties of Colloidal Bismuth Subcitrate (CBS, DE-NOL®) Scand. J. Gastroenterol., (1982), vol. 17, supp. 80, pp. 10-16.
WO2008004224A3 (en) * 2006-07-03 2009-04-09 Arie Levine Synergistic compositions for crohn's disease and inflammatory gastrointestinal disorders
US9884010B2 (en) * 2015-04-14 2018-02-06 Kenneth Davin Fine Dental hygiene systems
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GIROUX, REGI;FREEL, BARRY;GRAHAM, ROBERT;REEL/FRAME:010494/0934;SIGNING DATES FROM 19990930 TO 19991008
Owner name: JOSMAN LABORATORIES, CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ATHANIKAR, NARAYAN K.;REEL/FRAME:010709/0122